存档: 01/01/2019

Canagliflozin not associated with increased risk for fracture

Compared with a glucagon-line peptide-1 (GLP-1) agonist, canagliflozin was not associated with an increased risk for fracture in patients with type 2 diabetes at relatively low risk for fracture. Findings from a multidatabase ...

page1from1